$TNXP News

Tonix Pharma Presents Data From Real-World Claims Analysis Of Opioid Use In US Adults With Fibromyalgia At 2026 ASCP Annual Meeting

Tonix Pharmaceuticals' TNX-1500 Shows Favorable Safety Profile In Phase 1 Study As Phase 2 Kidney Transplant Trial Set For 2nd Half 2026

Tonix Pharmaceuticals' ISPOR 2026 Data Show 93.2% Comorbidity Burden And $29,896 Annual Inpatient Costs Among Fibromyalgia Patients

Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales

Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Announced An Agreement Effective May 1, 2026, With Group Purchasing Organization For Tonmya (Cyclobenzaprine HCL Sublingual Tablets)

TD Cowen Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $22

Tonix Pharma Presents Phase 1 Data And Plans For Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease In US At 4th Annual Ticks And Tickborne Diseases Symposium

Tonix Pharma Announces Oral Presentation And Two Poster Presentations On Preclinical Immuno-Oncology Portfolio At AACR Annual Meeting 2026

Tonix Pharmaceuticals Announces Publication Of The Paper "Steady-State Pharmacokinetic Properties Of TNX-102 SL, A Sublingual Tablet Formulation Of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing In Healthy Volunteers: A Randomized, Open-label Trial," In The Journal 'Clinical Pharmacology In Drug Development'

Tonix Pharmaceuticals Says Phase 1 Data of TNX-4800 (mAb 2217LS) For Preventing Lyme Disease Demonstrated Safety, Tolerability, And Pharmacokinetics Supportive Of Approximately Four Months Protection

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Announces First Participant Dosed In Phase 1 Investigator-Initiated Study To Evaluate Effect Of TNX-1900 On Trigeminal Nerve-Mediated Vasodilation Of Forehead Using Capsaicin As Well As Electrical Stimulation

Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026 - Slideshow

Tonix Pharmaceuticals Presents Phase 1 Data On TNX-4800, Long-Acting Human mAb Targeting OspA Of Borrelia Burgdorferi At World Vaccine Congress Washington 2026

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix To Present Preclinical Immuno-Oncology Data On Cancer Treatment Candidate TNX-1700 At AACR On April 21

Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum

OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR